Redx Pharma Plc

0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
Redx Pharma Plc LSE:REDX London Ordinary Share GB00BSNB6S51 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 28.00 541 01:00:00
Bid Price Offer Price High Price Low Price Open Price
27.00 29.00 28.00 28.00 28.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceutical Preparations 18.69 -18.01 -5.40 - 77.08
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:00 O 344 29.00 GBX

Redx Pharma (REDX) Latest News

Redx Pharma (REDX) Discussions and Chat

Redx Pharma Forums and Chat

Date Time Title Posts
08/3/202308:52Redx Pharma PLC511
02/7/202008:39REDX Pharma Discussion Thread Moderated157

Add a New Thread

Redx Pharma (REDX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-06-08 15:35:0029.0034499.76O
2023-06-08 13:35:0828.8517851.35O
2023-06-08 11:12:0328.8530.87O
2023-06-08 09:01:0728.8561.73O
2023-06-08 09:01:0628.8572.02O

Redx Pharma (REDX) Top Chat Posts

Top Posts
Posted at 23/2/2023 09:18 by pejaten
umm. terms seem unfair to REDX
Posted at 04/9/2022 14:59 by knitcraft
Put RXC004 into your search Engine then refer to my last post.

It gives real hope for specialist cancer and fibrosis treatment of previously extremly hard to treat tumours.

.....and potentially will give you the opportunity to buy into RedX before the news is widely available as to just who is responsible for this potential life-saving research.

Posted at 04/9/2022 14:37 by knitcraft
The following news item was first published in The "I" last week and has been subsequently picked up by other publications and TV news. The link below is to an ITV news item.

The intriguing and very important information that is missing from all the items, is the name of the company doing the research on RXC004.

It happens to be RedX and when that fact becomes widely known I would expect a reassessment of the value of RedX.

In June Trinity Delta,a reputable research company specialising in biomedicals, valued RedX shares on an undiluted basis at £1.38. The share price is currently 60p. Redx has at least 4 very promising research streams on the go.

From the research note in June 2022
Redx Pharma continues to deliver, with H122 results highlighting broad progress across the pipeline. The lead assets, RXC004, a porcupine inhibitor for oncology, and RXC007, a ROCK2 inhibitor for fibrosis, are advancing through Phase II and Phase I trials respectively, with further value inflection expected during 2022-23. Milestone receipts from AstraZeneca and Jazz Pharmaceuticals are tangible evidence of further progress with partnered programmes. Selection of RXC008, a GI targeted ROCK inhibitor as the next development candidate demonstrates earlier stage development is similarly bearing fruit. Our new rNPV-based valuation, updated to reflect H122 results and the May £34.3m (gross) equity raise, is £458m (vs £434m), or 138p/share.

It is worth looking at the company in more detail to fully appreciate what they are about. Look at the highly qualified team that has been assembled. Also check the lines of research they are pursuing and the major pharmaceutical companies they are associated with.
Also have look at the major shareholders involved.

Now look at this. Very few know this is about RedX. I suspect they soon will!

Posted at 23/12/2021 07:39 by wapper
Another great Milestone payment RNS. Well done REDX and Merry Christmas all holders.
Posted at 09/12/2021 08:29 by wapper
UK, 9 December 2021 - Redx (AIM: REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease, today announces that a milestone payment from Jazz Pharmaceuticals (NASDAQ: JAZZ) has been triggered as a result of entering the second year of the oncology research collaboration with the Company.

The milestone payment of $10 million arises in accordance with the terms of the research collaboration agreement announced on 9 September 2020. Under the agreement to discover and develop drug candidates for two cancer targets in the Ras/Raf/MAP kinase (MAPK) pathway, Redx is responsible for research and preclinical development activities up to Investigational New Drug (IND) submission. In addition to the $20 million in payments that have now been realised, Redx may receive up to a further $200 million from Jazz in development, regulatory and commercial milestone payments for each programme. The next milestone is payable upon successful IND submission and all subsequent milestones are contingent on successful completion of the relevant stages of development. In addition, Redx is eligible for tiered royalties in mid-single digit percentages, based on any future net sales.

Lisa Anson, Chief Executive Officer of Redx, commented: "We are extremely pleased to extend our productive oncology research collaboration with Jazz into its second year. This is based on advancing our programmes in this key signalling pathway and reflects Redx's core strength in discovering highly targeted potential drug candidates. We look forward to further progress in partnership with Jazz."

Redx continues to execute on its strategy, progressing its lead oncology and fibrosis programmes. These include the oral Porcupine inhibitor, RXC004, targeting Wnt-ligand driven tumours, which has recently entered a Phase 2 trial in genetically selected patients with microsatellite stable metastatic colorectal cancer (MSS mCRC) and the oral selective ROCK2 inhibitor, RXC007, being developed for idiopathic pulmonary fibrosis, where first in human studies commenced in June 2021.

Posted at 14/9/2021 09:58 by wapper
Added to my KOD holding with some of REDX cash
Posted at 10/9/2021 19:08 by knitcraft
Any update amrish? I think we would all appreciate your views on the future of Redx and it’s share price
Posted at 30/3/2021 12:33 by knitcraft
Looks like RedX is coming good for investors. Anyone who can be bothered to look more deeply into what has been achieved in the last 12 months will realise what an opportunity presents itself. They are on the cusp of tremendous results to benefit cancer and fibrosis patients. There are only 8% of the shares available in the market. Any positive news from just one of their research projects will transform RedX.They are presenting to a conference in the US in 10 days. Look into the background of the team for any reassurance on what they bring to the company. Funding is in place for two years of funding at the end of which the share price could be many multiples of today's breakout figure of 75.
Posted at 19/8/2020 18:46 by kennylogsin
Supercity - thanks for pointing out the 92% holding. I was running from the email alert issued by HL yesterday which opened with: Our Reference: 02648800

RedX Pharma plc - Your holding of xx,xxx Shares

Extended Cash Offer - Important information that requires your attention

What is happening?
Redmile Group recently bought approximately 39.5% of the RedX Pharma plc shares in issue at a price of 15.5p per share. Under UK company law the company has to offer to buy all remaining RedX shares at the same price. As a holder of RedX Pharma plc Shares in your Hargreaves Lansdown Stocks & Shares ISA you need to decide whether you wish to accept the Offer or not. At the time of writing RedX Pharma plc Shares are trading at 45p so you may get less cash by accepting this offer than you would trading your Shares in the market.

The other part I stated was at the bottom of the communication:
What happens if I do not accept the Offer?
If Redmile is able to obtain acceptances for 90% of the Company's Shares then they can force all remaining Shareholders to sell their Shares at the offer price. Redmile has indicated that if it receives acceptances in excess of 90% it does not currently intend to exercise its rights to compulsorily acquire the remaining RedX Pharma plc Shares.

If the Company receives acceptances in excess of 90% and does move to compulsorily acquire the remaining Shares, we will put forward your holding for acceptance of the Offer, as long as it remains open, in order to ensure that you receive proceeds in respect of your holding as soon as possible. If not you will receive the proceeds once the Compulsory Acquisition has been completed.

Redmile has stated that it intends to maintain RedX Pharma plc’s listing on AIM. However, if AIM is no longer considered a suitable market for RedX shares, Redmile may seek to move to a different market or trading facility.

Super - as I got this yesterday how is it 8 week old information? Was something issued somewhere else? Any advice welcome...

Posted at 11/8/2020 20:14 by global nomad
received reminder notice from iweb today...apologies to hahmedk for misconstruing his previous posts...para 3 and 4 are key but still a little vague...questions is still about selling on market asap or gambling on the listing remaining active after aug 24th - those paragraphs seem to suggest it might.

originally published by iweb on 19th June
Further to our previous correspondence, Redmile has received valid acceptances of the Offer in respect of approximately 91.76 percent of the existing issued share capital of REDX as of 30th April 2020.

Consequently, as Redmile has received acceptances under the Offer in respect of, and/or otherwise acquired 90 percent or more of the REDX shares in issue, Redmile is required to notify shareholders of their rights pursuant to the provisions of sections 983-985 of the Companies Act 2006 (The Act) to require Redmile to acquire the remaining REDX shares on the same terms as the Offer.

Please note, it is not Redmile's intention to exercise their right under Chapter 3 of Part 28 of the Act to acquire compulsorily the remaining Ordinary shares to which the Offer relates and in respect of which the Offer has not been accepted.

Redmile intends to maintain the admission of REDX Shares to trading on AIM immediately after the Offer. Should REDX be deemed to be unsuitable for admission to trading on AIM following Completion for any reason Redmile intends to investigate whether a listing on an alternative exchange or establishing an alternative trading facility would provide material benefits to shareholders through the continued ability to trade their shares.

Before making any decision please take into consideration all relevant factors of the event including the current share price and any possible tax implications. If you require any further information in making your decision please contact an appropriate professional advisor.

Please be aware that should you choose to accept the Offer, we do not yet know when the cash proceeds will be paid. However, we will notify you once your entitlement has been credited to your account.

Should you choose not to accept the Offer at this time, we will contact you again if the Offer is extended, the terms of the Offer change, or if we are notified that the Offer is closing.

Please note that acceptance to this Offer will only be applied to the number of shares you hold at the time we process your instruction.

Please note that should you elect to accept the Offer, your shares will be removed from your account after our Advice Date and will not be available for you to sell.

Should you wish to find more information about the Offer, please visit

What Happens If I Don't Elect ?

If you do not wish to accept the Offer at this stage then you should take no action.

Redx Pharma share price data is direct from the London Stock Exchange
Your Recent History
Redx Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230609 00:38:58